EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	10	("6673829" "6562847" "6888001" "20050215559" "6525070" "6903115").pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/28 14:46
L2	26871	(ohtake naya haga jitsuoka suga tokita kanatani).in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/28 14:50
L3	3	l2 and (heteroaryl$ and saturated).ti.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/28 14:50

```
=> b reg
FILE 'REGISTRY' ENTERED AT 16:09:26 ON 22 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 JUN 2007  HIGHEST RN 938223-21-3
DICTIONARY FILE UPDATES:  21 JUN 2007  HIGHEST RN 938223-21-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l30
L9                STR
```




```
VAR G1=C/N
REP G2=(0-3) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  13

STEREO ATTRIBUTES: NONE
L11         51529 SEA FILE=REGISTRY SSS FUL L9
L12               STR
```



REP G2=(0-3) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L15 47061 SEA FILE=REGISTRY SUB=L11 SSS FUL L12
L16 4468 SEA FILE=REGISTRY ABB=ON PLU=ON L11 NOT L15
L19 STR



REP G2=(0-3) C
NODE ATTRIBUTES:
NSPEC IS RC AT 14
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 3
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 8
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L21 491 SEA FILE=REGISTRY SUB=L16 SSS FUL L19
L22 STR



REP G1=(0-1) O
REP G2=(0-3) C
REP G3=(0-1) AK
REP G4=(0-1) N
VAR G5=AK/CY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 3
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 8
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L24 120 SEA FILE=REGISTRY SUB=L16 SSS FUL L22
L25 610 SEA FILE=REGISTRY ABB=ON PLU=ON (L21 OR L24)
L27 STR



REP G1=(0-1) O
REP G2=(0-3) C
REP G3=(0-1) AK
REP G4=(0-1) N
NODE ATTRIBUTES:
NSPEC IS RC AT 18
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 3
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 8
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L29 127 SEA FILE=REGISTRY SUB=L11 SSS FUL L27
L30 622 SEA FILE=REGISTRY ABB=ON PLU=ON (L25 OR L29)

=> b hcap
FILE 'HCAPLUS' ENTERED AT 16:09:49 ON 22 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Jun 2007 VOL 147 ISS 1
FILE LAST UPDATED: 21 Jun 2007 (20070621/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitind fhitstr retable 151 tot

L51 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1279121 HCAPLUS
DN 146:45523
TI Preparation of piperidine derivatives as histamine H3 receptor antagonists or inverse agonists
IN Ishikawa, Shiho; Sato, Nagaaki; Nagase, Tsuyoshi; **Tokita, Shigeru**; Wada, Toshihiro; Takahashi, Hidekazu
PA **Banyu** Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 302pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2006129826	A1	20061207	WO 2006-JP311155	20060529

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI 2005JP-0157739 A 20050530
2006JP-0115778 A 20060419
OS MARPAT 146:45523
GI



I



II

AB The title compds. [I; R1 = each (un)substituted aryl, 5- to 6-membered heteroaryl containing 1-3 heteroatoms selected from N, S, and O, heteroarylalkyl, aralkyl, or arylcarbonyl (wherein the heteroaryl group is optionally fused to Ph or pyridyl group); R2 = aryl, heteroaryl containing 1-3 heteroatoms selected from N, S, and O, cyano, lower alkyl, lower alkoxy, HO; or R1 and R2 together form an (un)substituted 5- to 6-membered aliphatic heterocyclyl containing 1-3 heteroatoms selected from N, S, and O optionally fused to a Ph or pyridyl group; R3 = (CH2)m1NR4R5, Q, Q1; R4, R5, R7, R8 = lower alkyl, halo-lower alkyl, cycloalkyl, halocycloalkyl; or NR4R5 or N R7R8 forms an (un)substituted 5- to 8-membered monocyclic ring or 6- to 8-membered bicyclic ring; m1 = an integer of 1-4; R8 = lower alkyl, cycloalkyl; m2 = an integer of 0-4; X1 = X2 = X3 = X4 = (un)substituted CH; at least one or two of X1-X4 = N and the rest = (un)substituted CH] or pharmaceutically acceptable salts thereof are prepared These compds. have

an antagonistic effect on the binding of histamine to a histamine H3 receptor or an inhibitory effect on the activity which a histamine H3 receptor constantly exhibits. They are useful for the prevention and/or treatment of obesity, diabetes, hormone secretion disorders, hyperlipidemia, gout, fatty liver, angina pectoris, hypertension, etc. Thus, a mixture of 8-(4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one, 5-bromo-2-methoxypyridine, potassium phosphate, CuI, and N,N'-dimethylethylenediamine in 1,4-dioxane was heated at 110° in a sealed tube with stirring to give 8-(4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl)-3-(6-methoxypyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one (II). II in vitro inhibited the binding of [3H]N-α-methylhistamine with IC50 of 0.09 nM. Number

CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 27

IT 13472-85-0P, 5-Bromo-2-methoxypyridine 94635-24-2P, 1-(4-Methoxyphenyl)piperidin-4-one 101803-06-9P, 5-Iodo-2-methoxypyrimidine 117607-13-3P, (2R)-2-Methylpyrrolidine hydrobromide 223684-72-8P, 1-Ethyl-1-methyl-4-oxopiperidinium chloride 259664-14-7P, 1-[4-(Benzyloxy)phenyl]piperidin-4-one 273217-89-3P **346665-40-5P**, tert-Butyl 4-[(5-nitropyridin-2-yl)oxy]piperidine-1-carboxylate 397277-96-2P, 4-[(1-Isopropylpiperidin-4-yl)oxy]aniline 398473-98-8P, 1-[3-(4-Iodophenoxy)propyl]piperidine 634904-81-7P, 8-(4-Methoxyphenyl)-1,4-dioxa-8-azaspiro[4.5]decane 862311-57-7P, 3-((2S)-2-Methylpyrrolidin-1-yl)propan-1-ol 862311-76-0P, 3-((3S)-3-Methylpiperidin-1-yl)propan-1-ol 862314-38-3P, 3-((2R)-2-Methylpyrrolidin-1-yl)propan-1-ol 870521-31-6P, 5-Bromo-2-isopropoxypyridine 870997-86-7P, (3S)-3-Methylpiperidine (R)-mandelate 899452-26-7P, 5-Bromo-2-(difluoromethoxy)pyridine 916344-14-4P, (3S)-1-(3-Bromopropyl)-3-methylpiperidine hydrobromide 916344-16-6P, (2S)-1-(3-Bromopropyl)-2-methylpyrrolidine hydrobromide 916344-17-7P, (2R)-1-(3-Bromopropyl)-2-methylpyrrolidine hydrobromide 916344-18-8P, 8-[4-(Benzyloxy)phenyl]-1,4-dioxa-8-azaspiro[4.5]decane 916344-21-3P, 4-(Aminomethyl)-1-[4-(benzyloxy)phenyl]piperidin-4-ol 916344-22-4P, 4-(Aminomethyl)-1-(4-methoxyphenyl)piperidin-4-ol 916344-23-5P, 4-(Aminomethyl)-1-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]piperidin-4-ol 916344-24-6P, 4-(Aminomethyl)-1-[4-[(1-isopropylpiperidin-4-yl)oxy]phenyl]piperidin-4-ol **916344-26-8P**, 4-(Aminomethyl)-1-[6-[(1-cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]piperidin-4-ol **916344-28-0P**, 4-(Aminomethyl)-1-[6-[(1-isopropylpiperidin-4-yl)oxy]pyridin-3-yl]piperidin-4-ol 916344-30-4P, 4-(Aminomethyl)-1-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]piperidin-4-ol 916344-32-6P, N-[[1-[4-(Benzyloxy)phenyl]-4-hydroxypiperidin-4-yl]methyl]-2-chloroacetamide 916344-34-8P, 2-Chloro-N-[[4-hydroxy-1-(4-methoxyphenyl)piperidin-4-yl]methyl]acetamide 916344-36-0P, 2-Chloro-N-[[1-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-4-hydroxypiperidin-4-yl]methyl]acetamide 916344-38-2P, 2-Chloro-N-[[4-hydroxy-1-[4-[(1-isopropylpiperidin-4-yl)oxy]phenyl]piperidin-4-yl]methyl]acetamide **916344-39-3P**, 2-Chloro-N-[[1-[6-[(1-cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-hydroxypiperidin-4-yl]methyl]acetamide 916344-40-6P, 9-[4-(Benzyloxy)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-41-7P, 9-(4-Methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-42-8P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-44-0P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916344-46-2P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-47-3P, tert-Butyl 9-[4-(benzyloxy)phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-carboxylate 916344-49-5P, tert-Butyl 9-(4-hydroxyphenyl)-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-carboxylate 916344-51-9P, 9-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-53-1P, 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-55-3P, 9-[4-[3-(Pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-57-5P, 9-[4-[3-((2S)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-59-7P, 9-[4-[3-((2R)-2-

Methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-61-1P, 8-(4-Methoxyphenyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-63-3P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-64-4P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916344-65-5P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916344-66-6P**, 8-[6-[(1-Isopropylpiperidin-4-yl)oxy]pyridin-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-67-7P, 8-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-68-8P, 8-(4-Hydroxyphenyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-69-9P, 8-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-70-2P **916344-71-3P**, 2-[(1-Cyclobutylpiperidin-4-yl)oxy]-5-nitropyridine **916344-73-5P**, 2-[(1-Isopropylpiperidin-4-yl)oxy]-5-nitropyridine 4-methylbenzenesulfonate **916344-74-6P**, 5-Amino-2-[(1-cyclobutylpiperidin-4-yl)oxy]pyridine **916344-75-7P**, 5-Amino-2-[(1-isopropylpiperidin-4-yl)oxy]pyridine 916344-76-8P, 1-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]piperidin-4-one 916344-77-9P, 1-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]piperidin-4-one **916344-78-0P**, 1-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]piperidin-4-one **916344-79-1P**, 1-[6-[(1-Isopropylpiperidin-4-yl)oxy]pyridin-3-yl]piperidin-4-one 916344-80-4P, 1-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]piperidin-4-one 916344-81-5P, 1'-[4-(3-Chloropropoxy)phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one 916344-87-1P, 9-[4-(Benzyloxy)phenyl]-4-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-88-2P, 9-(4-Hydroxyphenyl)-4-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-89-3P, 9-[4-(Benzyloxy)phenyl]-4-(3-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-90-6P, 9-(4-Hydroxyphenyl)-4-(3-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-91-7P, 9-[4-(Benzyloxy)phenyl]-4-(4-fluorophenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-92-8P, 4-(4-Fluorophenyl)-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-93-9P, 4-(6-Fluoropyridin-3-yl)-9-[4-(benzyloxy)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-94-0P 916344-95-1P, 9-(4-Benzyloxyphenyl)-4-(6-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-96-2P, 9-(4-Hydroxyphenyl)-4-(6-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-97-3P, 9-[4-(Benzyloxy)phenyl]-4-(6-methoxypyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-98-4P, 9-(4-Hydroxyphenyl)-4-(6-methoxypyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-99-5P, 9-[4-(Benzyloxy)phenyl]-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-00-1P, 9-(4-Hydroxyphenyl)-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-01-2P, 9-[4-(Benzyloxy)phenyl]-4-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-02-3P 916345-03-4P, 9-[4-(Benzyloxy)phenyl]-4-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-04-5P, 9-(4-Hydroxyphenyl)-4-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-05-6P, 9-[4-(Benzyloxy)phenyl]-4-isopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-06-7P, 9-(4-Hydroxyphenyl)-4-isopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-07-8P, 9-[4-(Benzyloxy)phenyl]-4-(1-ethylpropyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-08-9P, 4-(1-Ethylpropyl)-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-09-0P, 9-[4-(Benzyloxy)phenyl]-4-(2,2,2-trifluoroethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-10-3P, 9-(4-Hydroxyphenyl)-4-(2,2,2-trifluoroethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-11-4P, 1-[4-(Benzyloxy)phenyl]-4-[(cyclopropylamino)methyl]piperidin-4-ol 916345-13-6P, N-[[1-[4-(Benzyloxy)phenyl]-4-hydroxypiperidin-4-yl]methyl]-2-chloro-N-cyclopropylacetamide 916345-14-7P, 9-[4-(Benzyloxy)phenyl]-4-cyclopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-15-8P, 4-Cyclopropyl-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-16-9P, 1-[4-(Benzyloxy)phenyl]-4-[(cyclobutylamino)methyl]piperidin-4-ol 916345-17-0P, N-[[1-[4-(Benzyloxy)phenyl]-4-hydroxypiperidin-4-yl]methyl]-2-chloro-N-cyclobutylacetamide 916345-18-1P, 9-(4-Benzyloxyphenyl)-4-cyclobutyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-19-2P 916345-20-5P,

1-[4-(Benzyloxy)phenyl]-4-[(cyclopentylamino)methyl]piperidin-4-ol 916345-21-6P, N-[[1-[4-(Benzyloxy)phenyl]-4-hydroxypiperidin-4-yl]methyl]-2-chloro-N-cyclopentylacetamide 916345-22-7P, 9-[4-(Benzyloxy)phenyl]-4-cyclopentyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-23-8P, 4-Cyclopentyl-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-24-9P, 1-[4-(Benzyloxy)phenyl]-4-[(cyclohexylamino)methyl]piperidin-4-ol 916345-25-0P, N-[[1-[4-(Benzyloxy)phenyl]-4-hydroxypiperidin-4-yl]methyl]-2-chloro-N-cyclohexylacetamide 916345-26-1P, 9-[4-(Benzyloxy)phenyl]-4-cyclohexyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-27-2P, 4-Cyclohexyl-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-28-3P, 4-Benzyl-9-[4-(benzyloxy)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-29-4P, 4-Benzyl-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-30-7P, 4-(3-Fluorophenyl)-9-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-31-8P, 4-(3-Fluorophenyl)-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-32-9P, 4-(2-Fluorophenyl)-9-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-33-0P, 4-(2-Fluorophenyl)-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-34-1P, 4-(2-Fluoropyridin-4-yl)-9-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-35-2P, 4-(2-Fluoropyridin-4-yl)-9-(4-hydroxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-36-3P, 4-Ethyl-9-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-37-4P, 4-Methyl-9-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-38-5P, 8-(4-Methoxyphenyl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916345-39-6P, 8-(4-Hydroxyphenyl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916345-40-9P, 8-[4-(3-Chloropropoxy)phenyl]-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916345-41-0P, 3-[4-(Benzyloxy)phenyl]-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916345-42-1P, 9-(4-Methoxyphenyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-43-2P, 9-(4-Hydroxyphenyl)-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-44-3P, tert-Butyl 4-[4-(3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)phenoxy]piperidine-1-carboxylate 916345-45-4P, 9-[4-[(Piperidin-4-yl)oxy]phenyl]-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-46-5P, tert-Butyl 4-[4-(4-ethyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)phenoxy]piperidine-1-carboxylate 916345-47-6P, tert-Butyl 4-[4-[4-(6-fluoropyridin-3-yl)-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl]phenoxy]piperidine-1-carboxylate 916345-48-7P 916345-49-8P, 4-(6-Methoxypyridin-3-yl)-9-[4-[(piperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-50-1P 916345-51-2P, 4-Cyclobutyl-9-[4-[[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916345-52-3P, 1-[4-(Benzyloxy)phenyl]-4-[(trimethylsilyl)oxy]piperidine-4-carbonitrile 916345-53-4P, tert-Butyl 3-oxo-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-4-carboxylate **916345-54-5P**, 5-Nitro-2-[(piperidin-4-yl)oxy]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperidine derivs. as histamine H3 receptor antagonists or inverse agonists)

IT 916338-43-7P, 1'-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine] 916338-45-9P, 4-Phenyl-1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidin-4-ol 916338-47-1P, 3-Phenyl-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916338-49-3P, 1'-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one 916338-51-7P, 4-Phenyl-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916338-53-9P, 9-[4-[3-((2S)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916338-55-1P, 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916338-58-4P 916338-61-9P, 1-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-4-(pyridin-3-yl)piperidin-4-ol trifluoroacetate 916338-64-2P, 4-(4-Methoxyphenyl)-1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidin-4-ol trifluoroacetate 916338-67-5P, 5-Fluoro-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-

1,4'-piperidine] trifluoroacetate 916338-70-0P, 5-Fluoro-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one trifluoroacetate 916338-73-3P, 7-Fluoro-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one trifluoroacetate 916338-76-6P, 5-Methoxy-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one trifluoroacetate 916338-79-9P, 6-Methoxy-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one trifluoroacetate 916338-82-4P, 7-Methoxy-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one trifluoroacetate 916338-85-7P, 1'-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]-1-one trifluoroacetate 916338-88-0P, 1-(Methylsulfonyl)-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1,2-dihydrospiro[indole-3,4'-piperidine] trifluoroacetate 916338-91-5P, 1-(Ethylsulfonyl)-7-fluoro-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1,2-dihydrospiro[indole-3,4'-piperidine] trifluoroacetate 916338-94-8P, 1-(Ethylsulfonyl)-5-fluoro-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1,2-dihydrospiro[indole-3,4'-piperidine] trifluoroacetate 916338-97-1P, 4-tert-Butoxy-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine]-3-one trifluoroacetate 916339-00-9P, 1-(Ethylsulfonyl)-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1,2-dihydrospiro[indole-3,4'-piperidine] trifluoroacetate 916339-03-2P, 3,3-Dimethyl-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine] trifluoroacetate 916339-06-5P, 3-Methyl-1'-[4-[3-(piperidin-1-yl)propoxy]phenyl]-3H-spiro[2-benzofuran-1,4'-piperidine] trifluoroacetate 916339-09-8P, 1'-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3,4-dihydrospiro[chromene-2,4'-piperidine] trifluoroacetate 916339-12-3P, Phenyl[1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidin-4-yl]methanone trifluoroacetate 916339-15-6P, 4-Phenyl-1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidine-4-carbonitrile trifluoroacetate 916339-18-9P, 4-Benzyl-1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidine-4-carbonitrile trifluoroacetate 916339-21-4P, 4-Methyl-4-phenyl-1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidine trifluoroacetate 916339-24-7P, 4,4-Diphenyl-1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidine trifluoroacetate 916339-27-0P, 4-(3-Methoxyphenyl)-1-[4-[3-(piperidin-1-yl)propoxy]phenyl]piperidin-4-ol trifluoroacetate 916339-29-2P, 4-(4-Fluorophenyl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-31-6P, 4-(6-Fluoropyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-33-8P, 4-(4-Methoxyphenyl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-35-0P, 4-(4-Methylphenyl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-37-2P, 4-(6-Methoxypyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-39-4P, 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-4-(2-methylpyridin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-41-8P, 4-(3,4-Difluorophenyl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-43-0P, 4-(2,4-Difluorophenyl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-45-2P, 4-Phenyl-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-47-4P, 9-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-4-(pyridin-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-49-6P, 9-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-4-(pyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-51-0P, 4-[6-(Difluoromethoxy)pyridin-3-yl]-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-53-2P, 4-(6-Propoxypyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-55-4P, 4-(6-Isopropoxypyridin-3-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-57-6P, 4-[6-(Difluoromethoxy)pyridin-3-yl]-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-59-8P, 4-(2-Methoxypyrimidin-5-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-

4,9-diazaspiro[5.5]undecan-3-one 916339-61-2P 916339-63-4P, 4-(6-Methoxypyridin-3-yl)-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-65-6P, 4-(2-Methoxypyridin-5-yl)-9-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-67-8P, 4-(6-Methoxypyridin-3-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-69-0P, 4-(4-Fluorophenyl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-71-4P, 4-(4-Methoxyphenyl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-73-6P, 4-(1,3-Benzodioxol-5-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-75-8P, 4-(2-Methoxypyridin-4-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-77-0P, 4-(1-Methyl-6-oxo-1,6-dihydropyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-79-2P, 4-(2-Methoxypyridin-4-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-81-6P, 4-(1-Methyl-6-oxo-1,6-dihydropyridin-3-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-83-8P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(pyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-85-0P, 4-(5-Methylpyridin-2-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-87-2P, 4-(4-Methylpyridin-2-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-89-4P, 4-(3-Methylpyridin-2-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-91-8P, 4-(5-Methoxypyridin-2-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-93-0P, 4-(6-Methoxypyridin-2-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-95-2P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(3-thienyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-97-4P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(2-thienyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916339-99-6P, 4-(4-Methoxyphenyl)-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-01-7P, 4-(6-Fluoropyridin-3-yl)-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-03-9P, 4-[6-(Difluoromethoxy)pyridin-3-yl]-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-05-1P, 5-[9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]nicotinonitrile 916340-07-3P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(1,3-thiazol-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-09-5P, 3-(4-Fluorophenyl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-11-9P, 8-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3-(pyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-13-1P, 8-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3-(pyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-15-3P, 3-(6-Fluoropyridin-3-yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-17-5P, 8-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3-[6-(trifluoromethyl)pyridin-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-19-7P, 3-(2-Fluorophenyl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-21-1P, 3-(2-Fluoropyridin-4-yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-23-3P, 3-[6-(Difluoromethyl)pyridin-3-yl]-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-25-5P, 3-(5-Fluoropyridin-2-yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-27-7P, 3-(6-Fluoropyridin-2-yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-29-9P, 3-(3-Fluorophenyl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-31-3P, 3-(4-Methoxyphenyl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-33-5P, 3-(3-Methoxyphenyl)-8-

[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-35-7P, 3-(6-Methoxypyridin-3-yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-37-9P, 3-(6-Methylpyridin-3-yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-39-1P, 3-(2-Methoxyphenyl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-41-5P, 8-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-3-[4-(trifluoromethoxy)phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916340-43-7P, 4-(1-Ethyl-6-oxo-1,6-dihydropyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-45-9P, 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-4-(pyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-47-1P, 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-4-(pyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-49-3P, 4-(3-Methoxypyridin-2-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-51-7P, 4-(1-Ethyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-53-9P, 4-(1-Ethyl-5-methoxy-6-oxo-1,6-dihydropyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-55-1P, 4-(5-Methoxypyridin-2-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-57-3P, 4-(5-Fluoropyridin-2-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-59-5P, 5-[9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]nicotinonitrile 916340-61-9P, 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-4-(3-methylpyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-63-1P, 4-[1-(Difluoromethyl)-6-oxo-1,6-dihydropyridin-3-yl]-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-66-4P, 4-(1-Isopropyl-6-oxo-1,6-dihydropyridin-3-yl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-69-7P, 9-[4-[3-(Piperidin-1-yl)propoxy]phenyl]-4-(pyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-72-2P, 4-(3,4-Difluorophenyl)-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-74-4P, 4-(2,4-Difluorophenyl)-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-76-6P, 9-[4-[3-(Pyrrolidin-1-yl)propoxy]phenyl]-4-[6-(trifluoromethyl)pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-78-8P, 4-(6-Isopropoxypyridin-3-yl)-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-80-2P, 4-(2-Ethoxypyrimidin-5-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-82-4P, 4-(5-Methoxypyrazin-2-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-84-6P, 4-(4-Chlorophenyl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-86-8P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-[4-(trifluoromethyl)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-88-0P, 4-[9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]benzonitrile 916340-90-4P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-[4-(methylsulfonyl)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-92-6P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(pyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-94-8P, 4-(2-Methoxypyrimidin-5-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-97-1P, 4-(3-Methoxypyridin-2-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916340-99-3P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-01-0P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-[5-(trifluoromethyl)pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-03-2P, 4-(1-Methyl-1H-pyrazol-3-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-05-4P,

4-(1-Methyl-1H-pyrazol-4-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-07-6P, 4-(5-Methoxypyridin-3-yl)-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-10-1P, 9-[4-[3-((2S)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-12-3P, 4-(2-Methoxypyrimidin-5-yl)-9-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-14-5P, 5-[9-[4-[3-((2S)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]nicotinonitrile 916341-16-7P, 4-(5-Methoxypyridin-3-yl)-9-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-18-9P, 4-(5-Methoxypyrazin-2-yl)-9-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-20-3P, 4-(1-Methyl-1H-pyrazol-4-yl)-9-[4-[3-((S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-22-5P, 3-Ethyl-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-24-7P, 8-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-3-[4-(methylsulfonyl)phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-26-9P, 3-(2-Ethoxypyrimidin-5-yl)-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-28-1P, 3-(1-Methyl-1H-pyrazol-4-yl)-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-30-5P, 3-(1-Methyl-1H-pyrazol-3-yl)-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-32-7P, 5-[8-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl]nicotinonitrile 916341-34-9P, 8-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-3-(pyrazin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-36-1P, 3-(6-Methoxypyridin-3-yl)-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-38-3P, 3-(2-Methoxypyrimidin-5-yl)-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-40-7P, 3-(5-Methoxypyridin-3-yl)-8-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-42-9P, 3-(2-Methoxypyrimidin-5-yl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916341-44-1P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-46-3P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(6-methylpyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-48-5P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-[6-(difluoromethoxy)pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-50-9P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-isopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-52-1P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(6-isopropoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-54-3P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(2-isopropoxypyrimidin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-56-5P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(1-methyl-1H-pyrazol-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-58-7P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(5-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-60-1P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-[5-(trifluoromethyl)pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-62-3P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-[3-(trifluoromethyl)pyridin-2-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-64-5P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(6-methoxypyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-66-7P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(imidazo[1,2-a]pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-68-9P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-[4-(methylsulfonyl)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-70-3P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(pyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-72-5P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(3-methylpyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-74-7P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(5-methoxypyridin-2-yl)-1-

oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-76-9P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(4-fluorophenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-78-1P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(1-methyl-1H-pyrazol-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-80-5P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(2-methoxypyrimidin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-82-7P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-84-9P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(2-fluoropyridin-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-86-1P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-88-3P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-90-7P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-92-9P, 5-[9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]nicotinonitrile 916341-94-1P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(5-methoxypyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-96-3P, 4-Ethyl-9-[4-[(1-isopropylpiperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916341-98-5P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(2,2,2-trifluoroethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-00-2P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-[4-(methylsulfonyl)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-02-4P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-[5-(trifluoromethyl)pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-04-6P , 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(5-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-06-8P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(pyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-08-0P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(3-methoxypyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-10-4P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(2-methoxypyrimidin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-12-6P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(1-methyl-1H-pyrazol-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-14-8P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(1-methyl-1H-pyrazol-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-16-0P, 5-[9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]nicotinonitrile 916342-18-2P, 4-(2-Ethoxypyrimidin-5-yl)-9-[4-[(1-isopropylpiperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-20-6P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(5-methoxypyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-22-8P, 9-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-4-(6-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-24-0P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(1-methyl-1H-pyrazol-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-26-2P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(1-methyl-1H-pyrazol-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-28-4P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(2-isopropoxypyrimidin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-30-8P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-32-0P**, 5-[9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl]nicotinonitrile **916342-34-2P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-[4-(methylsulfonyl)phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-36-4P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(4-methoxyphenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-38-6P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(6-fluoropyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-40-0P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(2-fluoropyridin-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-42-2P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-[6-(difluoromethoxy)pyridin-3-yl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

916342-44-4P, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(4-fluorophenyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-46-6P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(6-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-48-8P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-50-2P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(2-methoxypyrimidin-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-52-4P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(6-methylpyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one **916342-54-6P**, 9-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-4-(5-methoxypyrazin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916342-56-8P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(6-methylpyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-58-0P, 5-[8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl]nicotinonitrile 916342-60-4P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(pyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-62-6P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(1-methyl-1H-pyrazol-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-64-8P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(1-methyl-1H-pyrazol-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-66-0P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(6-methoxypyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-68-2P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(imidazo[1,2-a]pyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-70-6P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(3-methylpyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-72-8P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(6-fluoropyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-74-0P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-[4-(methylsulfonyl)phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-76-2P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(2-fluoropyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-78-4P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-80-8P, 8-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-3-(2-methoxypyrimidin-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-82-0P, 3-Ethyl-8-[4-[(1-isopropylpiperidin-4-yl)oxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-84-2P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(1-methyl-1H-pyrazol-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-86-4P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(1-methyl-1H-pyrazol-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-88-6P, 5-[8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl]nicotinonitrile 916342-90-0P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(pyrazin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-92-2P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(5-methoxypyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-94-4P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(2-methoxypyrimidin-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-96-6P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(3-methoxypyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916342-98-8P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(6-methoxypyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-00-5P, 8-[4-[(1-Isopropylpiperidin-4-yl)oxy]phenyl]-3-(5-methoxypyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine derivs. as histamine H3 receptor antagonists or inverse agonists)

IT **916343-02-7P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(3-methylpyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-04-9P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(5-methoxypyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-06-1P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(5-fluoropyridin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-08-3P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-ethyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-10-7P**,

8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(2,2,2-trifluoroethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-12-9P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-[4-(methylsulfonyl)phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-14-1P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(2-ethoxypyrimidin-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-16-3P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(1-methyl-1H-pyrazol-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-18-5P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(1-methyl-1H-pyrazol-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-20-9P**, 5-[8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl]nicotinonitrile **916343-22-1P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(pyrazin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-24-3P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(6-methoxypyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-26-5P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(2-methoxypyrimidin-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-28-7P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-[5-(trifluoromethyl)pyridin-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-30-1P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(5-methoxypyridin-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-32-3P**, 8-[6-[(1-Cyclobutylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(5-methoxypyrazin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-34-5P**, 8-[6-[(1-Isopropylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(2-methoxypyrimidin-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-36-7P**, 5-[8-[6-[(1-Isopropylpiperidin-4-yl)oxy]pyridin-3-yl]-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl]nicotinonitrile **916343-38-9P**, 8-[6-[(1-Isopropylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(pyrazin-2-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one **916343-40-3P**, 8-[6-[(1-Isopropylpiperidin-4-yl)oxy]pyridin-3-yl]-3-(1-methyl-1H-pyrazol-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916343-42-5P, 4-(4-Methoxyphenyl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-44-7P, 4-(3-Methoxyphenyl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-46-9P, 4-(4-Fluorophenyl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-48-1P, 4-(6-Fluoropyridin-3-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-50-5P, 4-(6-Methoxypyridin-3-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-52-7P, 4-(6-Methoxypyridin-2-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-54-9P, 4-Methyl-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-56-1P, 4-Methyl-9-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-58-3P, 4-Ethyl-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-60-7P, 9-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-4-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-62-9P, 4-Isopropyl-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-64-1P, 4-Isopropyl-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-67-4P, 4-(1-Ethylpropyl)-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-68-5P, 9-[4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(2,2,2-trifluoroethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-70-9P, 4-Cyclopropyl-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-72-1P, 4-Cyclobutyl-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-74-3P, 4-Cyclobutyl-9-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-76-5P, 4-Cyclopentyl-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-78-7P 916343-80-1P, 4-Benzyl-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-82-3P, 4-Benzyl-9-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

916343-84-5P, 4-Benzyl-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-86-7P, 4-(3-Fluorophenyl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-88-9P, 4-(2-Fluorophenyl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-90-3P, 4-(2-Fluoropyridin-4-yl)-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-92-5P, 4-Ethyl-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-94-7P, 4-Ethyl-9-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-96-9P, 4-Methyl-9-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916343-98-1P, 8-[4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]phenyl]-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-00-8P, 3-(4-Hydroxyphenyl)-8-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 916344-02-0P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-04-2P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-06-4P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(6-fluoropyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-07-5P, 9-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-4-(6-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-08-6P, 9-[4-[(1-Cyclopropylpiperidin-4-yl)oxy]phenyl]-4-(6-methoxypyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-10-0P, 4-Cyclobutyl-9-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 916344-11-1P, 4-Cyclobutyl-9-[4-[(1-isopropylpiperidin-4-yl)oxy]phenyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine derivs. as histamine H3 receptor antagonists or inverse agonists)

IT **346665-40-5P**, tert-Butyl 4-[(5-nitropyridin-2-yl)oxy]piperidine-1-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperidine derivs. as histamine H3 receptor antagonists or inverse agonists)

RN 346665-40-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(5-nitro-2-pyridinyl)oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File	
Apodaca, R	2004			EP-----1556046 A1	HCAPLUS	
Apodaca, R	2004			US-0 @0 46 A1$ 0	HCAPLUS	*0
Apodaca, R	2004			WO--2004037257 A1	HCAPLUS	
Apodaca, R	2004			JP--2006505590 A		
Banyu Pharmaceutical Co	2005			EP-----1642898 A1	HCAPLUS	
Banyu Pharmaceutical Co	2005			AU--2004257025 A1	HCAPLUS	
Banyu Pharmaceutical Co	2005			WO--2005007644 A1	HCAPLUS	
Glaxo Group Ltd	2004			EP-----1567511 A1	HCAPLUS	
Glaxo Group Ltd	2004			AU--2003280380 A1	HCAPLUS	
Glaxo Group Ltd	2004			WO--2004035556 A1	HCAPLUS	
Glaxo Group Ltd	2004			US-20060025404	HCAPLUS	
Glaxo Group Ltd	2004			JP--2006508935 A		

L51 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:823314 HCAPLUS
DN 143:211923
TI Preparation of fused-ring 4-oxopyrimidine derivatives as histamine H3 receptor antagonists or inverse agonists
IN Nagase, Tsuyoshi; Sato, Nagaaki; **Kanatani, Akio**; **Tokita, Shigeru**
PA **Banyu** Pharmaceutical Co., Ltd., Japan
SO U.S. Pat. Appl. Publ., 84 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2005182045	A1	20050818	2005US-0058444	20050214
	AU2005212092	A1	20050825	2005AU-0212092	20050214
	CA---2555824	A1	20050825	2005CA-2555824	20050214
	WO2005077905	A1	20050825	2005WO-JP02664	20050214
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP---1717230	A1	20061102	2005EP-0710446	20050214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
	CN---1918128	A	20070221	CN 2005-80004939	20050214
	NO2006004089	A	20061106	2006NO-0004089	20060912
PRAI	2004JP-0037190	A	20040213		
	2005WO-JP02664	W	20050214		

OS MARPAT 143:211923
GI



I



II

AB The present invention provides fused-ring 4-oxopyrimidines (shown as I; variables defined below; e.g. 2-ethyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone (shown as II)) or pharmaceutically acceptable salts thereof, which, having histamine H3

receptor antagonist or inverse agonist activity, are useful in the prophylaxis or therapy of metabolic diseases, circulatory diseases, or nervous system diseases. For I: e.g. Ar is a divalent group formed by eliminating two H atoms from benzene; X1 = N, S, or O; R1 is a 5- to 6-membered heteroaryl group; Ring A is a 5- to 6-membered heteroaryl ring; R2 and R3 are amino or alkylamino groups; Y = CH or N; and X2 = -(CH2)nNR4R5 (R4 and R5 are lower alkyl groups, and n = 2-4). Although the methods of preparation are not claimed, .apprx.275 example prepns. are included. For example, II was prepared in 4 steps (98, 66, 82 and 47 %) starting from anthranilic acid and propionic anhydride and involving intermediates 2-ethyl-4H-3,1-benzoxazin-4-one, 2-ethyl-3-(4-hydroxyphenyl)-4(3H)-quinazolinone, and 2-ethyl-3-[4-(3-chloropropoxy)phenyl]-4(3H)-quinazolinone. Pharmacol. results are provided for II for the following tests: histamine analog coupling inhibition, antagonism of drinking behavior induced by R-α-methylhistamine (a histamine H3 receptor selective agonist), in vitro kinetics, and brain/cerebrospinal fluid activity.

IC ICM A61K-031/55
ICS A61K-031/517; C07D-043/02

INCL 514217060; 514266200; 514266220; 544284000

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 41151-73-9P, 3-[4-[3-(Diethylamino)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 41151-75-1P, 2-Methyl-3-[4-[2-(1-piperidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 862308-28-9P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-29-0P, 2-Methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-30-3P, 2-Methyl-3-[4-[3-(2-methyl-1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-31-4P, 3-[4-[3-(2,5-Dimethyl-1-pyrrolidinyl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862308-32-5P, 2-Methyl-3-[4-[4-(1-piperidinyl)butoxy]phenyl]-4(3H)-quinazolinone 862308-33-6P, 3-[4-[3-(1-Azepanyl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862308-34-7P, 3-[4-[3-(1-Azocanyl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862308-35-8P, 2-Methyl-3-[4-[3-(2-methyl-1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-36-9P, 2-Methyl-3-[4-[3-(4-methyl-1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-37-0P 862308-38-1P, 2-Methyl-3-[4-[3-(3-methyl-1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-39-2P, 3-[4-[3-(3,5-Dimethyl-1-piperidinyl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862308-40-5P, 2-Methyl-3-[3-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-41-6P, 3-[3-Bromo-4-[3-(1-piperidinyl)propoxy]phenyl]-2-ethyl-4(3H)-quinazolinone 862308-51-8P, 3-[4-[3-(1-Piperidinyl)propoxy]phenyl]-2-propyl-4(3H)-quinazolinone 862308-53-0P, 3-[4-[3-(1-Piperidinyl)propoxy]phenyl]-2-trifluoromethyl-4(3H)-quinazolinone 862308-55-2P, 2-Isopropyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-57-4P, 2,6-Dimethyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-59-6P, 7-Chloro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-61-0P, 2,8-Dimethyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-63-2P, 2-Ethyl-5-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-65-4P, 5-Fluoro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-73-4P, 5-Hydroxy-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone trifluoroacetate 862308-75-6P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-5-trifluoromethyl-4(3H)-quinazolinone 862308-78-9P, 7-Fluoro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-80-3P, 6-Fluoro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-82-5P, 6,7-Difluoro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-86-9P, 6-Chloro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-90-5P, 6,7-Dimethoxy-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-92-7P, 8-Chloro-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-94-9P,

8-Methoxy-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862308-96-1P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]benzo[g]quinazolin-4(3H)-one 862308-98-3P, 2,6-Dimethyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-02-2P, 2-Ethyl-5-methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-04-4P, 5-Fluoro-2-methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-06-6P, 2-Methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-5-trifluoromethyl-4(3H)-quinazolinone 862309-08-8P, 5-Chloro-2-methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-10-2P, 2-Ethyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-12-4P, 2,5-Dimethyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-14-6P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one 862309-16-8P, 2-Methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one 862309-18-0P, 6-Chloro-2-methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862309-20-4P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862309-24-8P, 2-Methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one 862309-26-0P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one 862309-28-2P, 2-Methyl-3-[2-[3-(1-piperidinyl)propoxy]-5-pyrimidinyl]-4(3H)-quinazolinone 862309-32-8P, 2,5-Dimethyl-3-[2-[3-(1-piperidinyl)propoxy]-5-pyrimidinyl]-4(3H)-quinazolinone 862309-34-0P, 2-Ethyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one 862309-40-8P, 2-Ethyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862309-42-0P, 2-Ethyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862309-44-2P, 2-Ethyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one 862309-46-4P, 2-Ethyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one 862309-50-0P, 3-[4-[3-(1-Piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-59-9P, 6-(Butyrylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-61-3P, 6-(Hexanoylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-63-5P, 6-(Benzoylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-65-7P, 6-[(2-Phenylacetyl)amino]-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-67-9P, 6-(2-Naphthoylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-69-1P, 2-Methyl-6-[(methylsulfonyl)amino]-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-71-5P, 2-Methyl-6-[(methylsulfonyl)amino]-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-75-9P, 7-(Acetylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-77-1P, 7-(Butyrylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-81-7P, 7-(Hexanoylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-83-9P, 7-(Benzoylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-85-1P, 7-[(2-Phenylacetyl)amino]-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-87-3P, 7-(2-Naphthoylamino)-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-89-5P, 6-[Acetyl(methyl)amino]-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-91-9P, 2-Methyl-6-phenyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-93-1P, 2-Methyl-6-(4-methylphenyl)-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-95-3P, 2-Methyl-6-(3-methylphenyl)-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862309-98-6P, 2-Methyl-6-(2-methylphenyl)-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862310-00-7P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-6-(3-pyridyl)-4(3H)-quinazolinone 862310-02-9P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-6-(4-pyridyl)-4(3H)-quinazolinone 862310-04-1P, 2-Methyl-5-phenyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862310-06-3P, 2-Methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-6-(2-pyridyl)-4(3H)-

quinazolinone 862310-08-5P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-15-4P, 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-17-6P, 3-[4-(1-Cyclohexyl-4-piperidinyloxy)phenyl]-2-methyl-4(3H)-quinazolinone 862310-19-8P, 3-[4-(1-Isopropyl-4-piperidinyloxy)phenyl]-2-methyl-4(3H)-quinazolinone 862310-21-2P, 3-[4-(1-Ethyl-4-piperidinyloxy)phenyl]-2-methyl-4(3H)-quinazolinone 862310-23-4P, 3-[4-(1-Butyl-4-piperidinyloxy)phenyl]-2-methyl-4(3H)-quinazolinone 862310-25-6P, 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methyl-5-trifluoromethyl-4(3H)-quinazolinone 862310-35-8P, 3-[4-(1-Cyclopentyl-4-piperidinyloxy)phenyl]-2,5-dimethyl-4(3H)-quinazolinone 862310-37-0P, 7-Chloro-3-[4-[(1-cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-40-5P, 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2,6-dimethyl-4(3H)-quinazolinone 862310-42-7P, 6-Chloro-3-[4-[(1-cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-44-9P, 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-6-methoxy-2-methyl-4(3H)-quinazolinone 862310-47-2P, 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methylpyrido[2,3-d]pyrimidin-4(3H)-one 862310-50-7P, 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methylpyrido[4,3-d]pyrimidin-4(3H)-one 862310-57-4P, 3-[4-[(1-Cyclopentyl-4-piperidinyl)oxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862310-59-6P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2,5-dimethyl-4(3H)-quinazolinone 862310-66-5P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-methyl-5-trifluoromethyl-4(3H)-quinazolinone 862310-68-7P, 5-Chloro-3-[4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-70-1P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-methylpyrido[4,3-d]pyrimidin-4(3H)-one 862310-72-3P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-ethylpyrido[4,3-d]pyrimidin-4(3H)-one 862310-74-5P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-methylpyrido[2,3-d]pyrimidin-4(3H)-one 862310-76-7P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-ethylpyrido[2,3-d]pyrimidin-4(3H)-one 862310-82-5P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862310-84-7P, 3-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-2-ethylpyrido[3,4-d]pyrimidin-4(3H)-one 862310-86-9P, 2-Phenyl-3-[4-[3-(piperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862310-88-1P, cis-2-Methyl-3-[4-[[4-(1-pyrrolidinyl)cyclohexyl]oxy]phenyl]-4(3H)-quinazolinone 862310-90-5P, trans-2-Methyl-3-[4-[[4-(1-pyrrolidinyl)cyclohexyl]oxy]phenyl]-4(3H)-quinazolinone 862310-94-9P, 3-[4-[(1-Cyclopentyl-3-pyrrolidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-96-1P, 3-[4-[(1-Cyclobutyl-3-pyrrolidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-98-3P, 3-[4-[(1-Cyclopentyl-4-azepanyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862311-01-1P, 3-[4-[(1-Cyclobutyl-4-azepanyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862311-03-3P, 3-Methyl-2-[4-[3-(1-piperidinyl)propoxy]phenyl]-1(2H)-isoquinolinone 862311-11-3P, 2-[4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl]-3-methyl-1(2H)-isoquinolinone 862311-13-5P, 2-Methyl-3-[4-[[trans-3-(1-pyrrolidinyl)cyclopentyl]oxy]phenyl]-4(3H)-quinazolinone 862311-19-1P 862311-21-5P, 3-[4-[3-(8-Azabicyclo[3.2.1]oct-8-yl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862311-24-8P, 3-[4-[3-(3,3-Difluoropyrrolidin-1-yl)propoxy]phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone trifluoroacetate 862311-27-1P, 3-[4-[3-((3R)-3-Fluoropyrrolidin-1-yl)propoxy]phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone trifluoroacetate 862311-31-7P, 3-[4-[3-(4,4-Difluoropiperidin-1-yl)propoxy]phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone trifluoroacetate 862311-34-0P, 3-[4-[3-(4-Fluoropiperidin-1-yl)propoxy]phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone trifluoroacetate 862311-37-3P, 3-[4-[3-(3,3-Difluoropiperidin-1-yl)propoxy]phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone trifluoroacetate 862311-41-9P, 3-[4-[3-(3-Fluoropiperidin-1-yl)propoxy]phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone trifluoroacetate 862311-44-2P, 2-Methyl-3-[4-[3-((3R)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-47-5P 862311-49-7P,

2-Methyl-3-[4-[3-(3-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-51-1P, 5-Methoxy-3-[4-[3-(piperidin-1-yl)propoxy]phenyl]-2-propyl-4(3H)-quinazolinone 862311-53-3P, 5-Methoxy-2-propyl-3-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-55-5P, 2-Methyl-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-62-4P, 2,5-Dimethyl-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-64-6P, 2,6-Dimethyl-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-66-8P, 2-Ethyl-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-68-0P, 6-Chloro-2-ethyl-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862311-72-6P, 6-Methoxy-2-methyl-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-74-8P, 2-Methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-82-8P, 5-Bromo-2-methyl-3-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-84-0P, 5-Fluoro-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-86-2P, 2-Ethyl-5-fluoro-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862311-88-4P, 6-Fluoro-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862311-91-9P, 2-Ethyl-6-fluoro-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862311-97-5P, 2-Methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one monohydrochloride 862312-00-3P, 2-Ethyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one monohydrochloride 862312-02-5P, 2-Methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one 862312-03-6P, 2-Methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one monotosylate 862312-05-8P, 2-Ethyl-5-methoxy-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone hydrochloride 862312-07-0P, 2-Methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862312-09-2P, 2-Ethyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862312-11-6P, 8-Fluoro-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone hydrochloride 862312-13-8P, 8-Fluoro-2-methyl-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-4(3H)-quinazolinone hydrochloride 862312-15-0P, 6-(2-Fluoroethoxy)-2-methyl-3-[4-[3-(piperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-17-2P, 6-(2-Fluoroethoxy)-2-methyl-3-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-19-4P, 5-Methoxy-2-methyl-3-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-23-0P, 6-Methoxy-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-25-2P, 6-(Difluoromethoxy)-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-29-6P, 5-(Difluoromethoxy)-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-31-0P, 7-Methoxy-2-methyl-3-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-33-2P, 7-Methoxy-2-methyl-3-[4-[3-(piperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-36-5P, 7-Methoxy-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-38-7P, 5-Methoxy-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-43-4P, 6-Methoxy-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-46-7P, 7-Methoxy-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-48-9P, 3-[4-[3-(Azepan-1-yl)propoxy]phenyl]-2,6-dimethyl-4(3H)-quinazolinone 862312-50-3P, 3-[4-[3-(Azepan-1-yl)propoxy]phenyl]-5-fluoro-2-methyl-4(3H)-quinazolinone 862312-54-7P, 3-[4-[3-(Azepan-1-yl)propoxy]phenyl]-7-fluoro-2-methyl-4(3H)-quinazolinone 862312-56-9P, 3-[4-[3-(Azepan-1-yl)propoxy]phenyl]-5-methoxy-2-methyl-4(3H)-quinazolinone 862312-58-1P, 3-[4-[3-(Azepan-1-yl)propoxy]phenyl]-6-methoxy-2-methyl-4(3H)-quinazolinone 862312-60-5P 862312-64-9P, 3-[4-[3-(Azepan-1-

yl)propoxy]phenyl]-2-methylpyrido[4,3-d]pyrimidin-4(3H)-one 862312-66-1P, 2-Methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862312-68-3P, 2,5-Dimethyl-3-[2-methoxy-4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862312-78-5P, 6-Fluoro-3-[2-methoxy-4-[3-(piperidin-1-yl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862312-80-9P, 6-Fluoro-3-[2-methoxy-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862312-82-1P, 3-[2-Methoxy-4-[3-(piperidin-1-yl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862312-84-3P, 3-[2-Methoxy-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862312-88-7P, 3-[3-Bromo-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone 862312-94-5P, 2,5-Dimethyl-3-[2-(2-fluoroethoxy)-4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862312-98-9P, 3-[2-(2-Fluoroethoxy)-4-[3-(1-piperidinyl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862313-00-6P, 3-[2-(2-Fluoroethoxy)-4-[3-(1-piperidinyl)propoxy]phenyl]-2-methylpyrido[4,3-d]pyrimidin-4(3H)-one 862313-06-2P, 6-Methoxy-2-methyl-3-[4-[3-(piperidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862313-08-4P, 6-Methoxy-2-methyl-3-[4-[3-(pyrrolidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862313-10-8P, 2-Ethyl-6-methoxy-3-[4-[3-(1-piperidinyl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862313-12-0P, 2-Ethyl-6-methoxy-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862313-14-2P, 6-Methoxy-3-[2-methoxy-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862313-20-0P, 3-[2-(2-Fluoroethoxy)-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-6-methoxycarbonyl-2-methyl-4(3H)-quinazolinone 862313-22-2P, 3-[3-Fluoro-4-[3-(1-piperidinyl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862313-24-4P, 3-[2-Fluoro-4-[3-(1-piperidinyl)propoxy]phenyl]-2-methyl-4(3H)-quinazolinone 862313-26-6P, 2-Methyl-3-[3-methyl-4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862313-28-8P

, 2-Methyl-3-[2-methyl-4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862313-30-2P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]-2-methoxyphenyl]-2,5-dimethyl-4(3H)-quinazolinone 862313-32-4P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-6-methoxy-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862313-34-6P, 3-[4-[(1-Cyclopentylpiperidin-4-yl)oxy]phenyl]-6-methoxy-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862313-40-4P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]-3-fluorophenyl]-2-methyl-4(3H)-quinazolinone 862313-42-6P, 3-[4-[(1-Cyclopentylpiperidin-4-yl)oxy]-3-fluorophenyl]-2-methyl-4(3H)-quinazolinone 862313-44-8P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]-2-fluorophenyl]-2-methyl-4(3H)-quinazolinone 862313-46-0P, 3-[4-[(1-Cyclopentylpiperidin-4-yl)oxy]-2-fluorophenyl]-2-methyl-4(3H)-quinazolinone 862313-48-2P, 2-Methyl-3-[4-[(1-cyclobutylpiperidin-4-yl)oxy]-2-methylphenyl]-4(3H)-quinazolinone hydrochloride 862313-50-6P, 2-Methyl-3-[4-[(1-cyclopentylpiperidin-4-yl)oxy]-2-methylphenyl]-4(3H)-quinazolinone 862313-52-8P, 3-[4-[(1-Cyclopentylpiperidin-4-yl)oxy]-2-(2-fluoroethoxy)phenyl]-2-methylpyrido[4,3-d]pyrimidin-4(3H)-one 862313-54-0P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-5-(2-fluoroethoxy)-2-methyl-4(3H)-quinazolinone 862313-58-4P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]-2-(2-fluoroethoxy)phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one **862313-60-8P**, 3-[2-[(1-Cyclobutylpiperidin-4-yl)oxy]pyrimidin-5-yl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone 862313-68-6P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-5-methoxy-2-propyl-4(3H)-quinazolinone 862313-72-2P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-2-ethyl-6-fluoropyrido[3,4-d]pyrimidin-4(3H)-one 862313-74-4P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-6-fluoro-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862313-76-6P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-5-fluoro-2-methyl-4(3H)-quinazolinone 862313-78-8P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-6-fluoro-2-methyl-4(3H)-quinazolinone 862313-80-2P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-7-fluoro-2-methyl-4(3H)-quinazolinone 862313-82-4P, 3-[4-[(1-Cyclobutylpiperidin-4-

yl)oxy]phenyl]-6,7-difluoro-2-methyl-4(3H)-quinazolinone 862313-84-6P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-2-ethyl-5-methyl-4(3H)-quinazolinone 862313-86-8P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-2-ethyl-5-fluoro-4(3H)-quinazolinone 862313-88-0P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-2-ethyl-5-methoxy-4(3H)-quinazolinone 862313-90-4P, 5-Chloro-3-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-2-ethyl-4(3H)-quinazolinone 862313-92-6P, 3-[3-Bromo-4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-5-fluoro-2-methyl-4(3H)-quinazolinone 862313-94-8P, 3-[3-Bromo-4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]-2,5-dimethyl-4(3H)-quinazolinone 862313-98-2P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-2-ethyl-5-(trifluoromethyl)-4(3H)-quinazolinone hydrochloride 862314-00-9P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-8-fluoro-2-methyl-4(3H)-quinazolinone 862314-02-1P, 2-[3-(Benzyloxy)propyl]-3-[4-[(1-cyclopentylpiperidin-4-yl)oxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one 862314-08-7P, 2-[2-(Allyloxy)ethyl]-6-chloro-3-[4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862314-16-7P, 3-[4-[(1-Cyclopropylpiperidin-4-yl)oxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862314-18-9P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-6-(difluoromethoxy)-2-methyl-4(3H)-quinazolinone 862314-20-3P, 3-[4-[(1-Cyclobutylpiperidin-4-yl)oxy]phenyl]-7-methoxy-2-methyl-4(3H)-quinazolinone 862314-26-9P, 6-Chloro-3-[2-(2-fluoroethoxy)-4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862314-28-1P, 2-Ethyl-6-methoxy-3-[4-[3-((2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862314-30-5P, 2-Ethyl-6-methoxy-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one hydrochloride 862314-32-7P, 6-Methoxy-3-[2-methoxy-4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one 862314-36-1P, 6-Methoxy-2-methyl-3-[4-[3-((3S)-3-methylpiperidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862314-37-2P, 6-Methoxy-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one 862314-39-4P, 2,5-Dimethyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862314-40-7P, 2-Methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-5-(trifluoromethyl)-4(3H)-quinazolinone 862314-41-8P, 5-Chloro-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862314-42-9P, 5-Fluoro-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862314-43-0P, 6-Fluoro-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862314-44-1P, 7-Fluoro-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862314-45-2P, 8-Fluoro-2-methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862314-46-3P, 2,6-Dimethyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-4(3H)-quinazolinone 862314-47-4P, 2-Methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]pyrido[2,3-d]pyrimidin-4(3H)-one 862314-48-5P, 2-Methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]pyrido[4,3-d]pyrimidin-4(3H)-one 862314-49-6P, 2-Methyl-3-[4-[3-((2R)-2-methylpyrrolidin-1-yl)propoxy]phenyl]pyrido[3,4-d]pyrimidin-4(3H)-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of fused ring 4-oxopyrimidine derivs. as histamine H3 receptor antagonists or inverse agonists)

IT 1022-46-4P, 2-Phenyl-4H-3,1-benzoxazin-4-one 1462-86-8P, 3-Aminopyridine-2-carboxylic acid 2852-91-7P, 2-(2-Oxopropyl)benzoic acid 2916-09-8P, 2-Ethyl-4H-3,1-benzoxazin-4-one 6760-99-2P 16750-67-7P, 4-Amino-2-bromophenol 22428-87-1P, 1,4-Dioxaspiro[4.5]decan-8-ol 38527-50-3P, 6-Methoxy-2-methyl-4H-3,1-benzoxazin-4-one 38876-67-4P, 2-Bromo-6-nitrobenzoic acid 60288-19-9P, 2,5-Dimethyl-4H-3,1-benzoxazin-4-one 66122-70-1P, 3-Methyl-1H-isochroman-1-one 92374-75-9P, 1-[3-(4-Nitrophenoxy)propyl]piperidine 99059-02-6P, 3-(1-Hydroxyethyl)-2-benzofuran-1(3H)-one 155619-00-4P, 2-Ethyl-3-(4-hydroxyphenyl)-4(3H)-quinazolinone 162402-39-3P, 4-(4-Nitrophenoxy)piperidine 251552-34-8P, 4-[3-(1-

Piperidinyl)propoxy]aniline 343965-79-7P, 4-[3-(1-Pyrrolidinyl)propoxy]aniline 834878-12-5P, (2S)-2-Methylpyrrolidine hydrobromide 862308-27-8P, 2-Ethyl-3-[4-(3-chloropropoxy)phenyl]-4(3H)-quinazolinone 862308-42-7P, 2-Bromo-1-(3-chloropropoxy)-4-nitrobenzene 862308-44-9P, 3-Bromo-4-(3-chloropropoxy)aniline 862308-45-0P, 3-[3-Bromo-4-(3-chloropropoxy)phenyl]-2-ethyl-4(3H)-quinazolinone 862308-49-4P, 5-Amino-2-[3-(1-piperidinyl)propoxy]pyrimidine 862309-00-0P, 4-[3-(1-Pyrrolidinyl)propoxy]aniline ditosylate 862309-30-6P, 5-Nitro-2-[3-(piperidin-1-yl)propoxy]pyrimidine 862309-55-5P, 6-Amino-2-methyl-3-[4-[3-(1-piperidinyl)propoxy]phenyl]-4(3H)-quinazolinone 862310-10-9P, 3-[4-[(1-tert-Butoxycarbonyl-4-piperidinyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862310-13-2P, 2-Methyl-3-[4-(4-piperidinyloxy)phenyl]-4(3H)-quinazolinone 862310-27-8P, 1-Cyclopentyl-4-(4-nitrophenoxy)piperidine 862310-29-0P, 4-[(1-Cyclopentylpiperidin-4-yl)oxy]aniline 862310-31-4P, 2-Methyl-5-trifluoromethyl-4H-3,1-benzoxazin-4-one 862310-33-6P, 4-[(1-Cyclobutyl-4-piperidinyl)oxy]aniline 862310-62-1P, 4-[(1-Cyclobutyl-4-piperidinyl)oxy]aniline monotosylate 862310-92-7P, 2-Methyl-3-[4-[(4-oxocyclohexyl)oxy]phenyl]-4(3H)-quinazolinone 862311-07-7P, 2-(4-Methoxyphenyl)-3-methyl-1(2H)-isoquinolinone 862311-09-9P, 2-(4-Hydroxyphenyl)-3-methyl-1(2H)-isoquinolinone 862311-15-7P, 3-[4-[(3-Hydroxycyclopentyl)oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862311-17-9P, 3-[4-[[3-[(Methylsulfonyl)oxy]cyclopentyl]oxy]phenyl]-2-methyl-4(3H)-quinazolinone 862311-57-7P, 3-((2S)-2-Methylpyrrolidin-1-yl)propan-1-ol 862311-60-2P, 4-[3-((2S)-2-Methylpyrrolidin-1-yl)propoxy]aniline 862311-76-0P, 3-((3S)-3-Methylpiperidin-1-yl)propan-1-ol 862311-80-6P, 4-[3-((3S)-3-Methylpiperidin-1-yl)propoxy]aniline monotosylate 862312-41-2P, 4-[3-((2R)-2-Methylpyrrolidin-1-yl)propoxy]aniline monotosylate 862312-92-3P, 6-Chloro-3-[2-hydroxy-4-[3-(piperidin-1-yl)propoxy]phenyl]-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one **862313-62-0P**, tert-Butyl 4-[(5-nitropyrimidin-2-yl)oxy]piperidine-1-carboxylate **862313-64-2P**, tert-Butyl 4-[(5-aminopyrimidin-2-yl)oxy]piperidine-1-carboxylate **862313-66-4P**, 2-Methyl-3-[2-(piperidin-4-yloxy)pyrimidin-5-yl]-5-(trifluoromethyl)-4(3H)-quinazolinone 862314-04-3P, 2-[[4-(Benzyloxy)butanoyl]amino]nicotinic acid 862314-06-5P, 2-[3-(Benzyloxy)propyl]-4H-pyrido[2,3-d][1,3]oxazin-4-one 862314-14-5P, 1-Cyclopropyl-4-(4-nitrophenoxy)piperidine 862314-60-1P, 4-[3-(Pyrrolidin-1-yl)butoxy]aniline 862314-67-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused ring 4-oxopyrimidine derivs. as histamine H3 receptor antagonists or inverse agonists)

IT **862313-60-8P**, 3-[2-[(1-Cyclobutylpiperidin-4-yl)oxy]pyrimidin-5-yl]-2-methyl-5-(trifluoromethyl)-4(3H)-quinazolinone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of fused ring 4-oxopyrimidine derivs. as histamine H3 receptor antagonists or inverse agonists)

RN 862313-60-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[2-[(1-cyclobutyl-4-piperidinyl)oxy]-5-pyrimidinyl]-2-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L51 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:74112 HCAPLUS

DN 142:176868
TI Preparation of heterocyclic compounds as histamine H3 receptor antagonists/inverse agonists
IN **Ohtake, Norikazu; Naya, Akira; Haga, Yuji; Jitsuoka, Makoto; Suga, Takuya; Yoshimoto, Ryo ; Tokita, Shigeru; Kanatani, Akio**
PA **Banyu** Pharmaceutical Co., Ltd, Japan
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005007644	A1	20050127	2004WO-JP09272	20040624 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU2004257025	A1	20050127	2004AU-0257025	20040624 <--
CA---2529790	A1	20050127	2004CA-2529790	20040624 <--
EP---1642898	A1	20060405	2004EP-0746741	20040624 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN---1812981	A	20060802	CN 2004-80018205	20040624 <--
US2006178375	A1	20060810	2005US-0561115	20051215 <--
PRAI 2003JP-0184879	A	20030627 <--		
2004WO-JP09272	W	20040624 <--		

OS MARPAT 142:176868
GI



I



AB The title compds. I [each of X1, X2 and X3 independently represents N or CH; W represents the formula T1, etc.; m = 0 - 3; and Y represents (O)jL1(CO)p(M)iQ1; j, p, i = 0 or 1; L1 = alkylene, single bond; M = O, etc.; Q1 = cyano, etc; R = cyano, etc.] are prepared Thus, 2-(1-cyclopentylpiperidin-4-yloxy)-5-(4-cyanophenyl)pyrimidine was prepared in a multistep process from 2-chloro-5-bromopyrimidine and 1-tert-butoxycarbonyl-4-hydroxypiperidine. In an in vitro assay for inhibition of a histamine analog binding to the H3 receptors, compds. of this invention showed IC50 values of 0.45 nM to 1.9 nM. Processes for preparing I are disclosed. Formulations are given.
IC ICM C07D-401/12
ICS C07D-401/14; C07D-403/12; C07D-405/14; C07D-409/14; C07D-413/14; C07D-487/04; A61K-031/506; A61K-031/4545; A61K-031/501; A61P-001/16; A61P-003/00; A61P-003/04; A61P-003/06; A61P-003/10; A61P-007/00; A61P-009/10; A61P-009/12; A61P-013/12; A61P-019/06
CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
IT **832735-10-1P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic compds. as histamine H3 receptor antagonists/inverse agonists)

IT 832734-48-2P 832734-50-6P 832734-53-9P 832734-55-1P 832734-57-3P
832734-59-5P 832734-60-8P 832734-62-0P 832734-64-2P 832734-66-4P
832734-68-6P 832734-70-0P 832734-72-2P 832734-74-4P 832734-76-6P
832734-78-8P **832734-80-2P** **832734-82-4P** 832734-84-6P
832734-85-7P 832734-86-8P 832734-87-9P 832734-88-0P
832734-89-1P 832734-90-4P 832734-91-5P 832734-92-6P 832734-93-7P
832734-94-8P 832734-95-9P 832734-96-0P 832734-97-1P 832734-98-2P
832734-99-3P 832735-00-9P 832735-01-0P 832735-02-1P 832735-03-2P
832735-04-3P 832735-05-4P 832735-06-5P 832735-07-6P 832735-08-7P
832735-09-8P 832735-11-2P 832735-12-3P 832735-13-4P 832735-14-5P
832735-15-6P 832735-16-7P 832735-17-8P 832735-18-9P 832735-19-0P
832735-20-3P 832735-21-4P 832735-22-5P 832735-23-6P 832735-24-7P
832735-25-8P 832735-26-9P 832735-27-0P 832735-28-1P 832735-29-2P
832735-30-5P 832735-31-6P 832735-32-7P 832735-33-8P 832735-34-9P
832735-35-0P 832735-36-1P 832735-38-3P 832735-39-4P 832735-40-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as histamine H3 receptor antagonists/inverse agonists)

IT 52240-10-5P, 6-(4-Cyanophenyl)-2H-pyridazin-3-one 832735-41-8P
832735-42-9P 832735-43-0P 832735-44-1P 832735-45-2P 832735-46-3P
832735-47-4P 832735-48-5P 832735-49-6P **832735-50-9P**
832735-51-0P 832735-52-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. as histamine H3 receptor antagonists/inverse agonists)

IT **832735-10-1P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic compds. as histamine H3 receptor antagonists/inverse agonists)

RN 832735-10-1 HCAPLUS
CN Piperidine, 1-[[2-[(1-cyclopentyl-4-piperidinyl)oxy]-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Abbott Laboratories	2002			WO-----0206223 A1	HCAPLUS
Abbott Laboratories	2002			EP-----1301480 A1	HCAPLUS
Abbott Laboratories	2002			BR---200108088 A	
Abbott Laboratories	2002			AU---200173384 A	
Abbott Laboratories	2002			MX--2002012851 A1	
Abbott Laboratories	2002			JP--2004509076 A	
Astrazeneca Ab	2001			WO-----0177101 A1	HCAPLUS
Astrazeneca Ab	2001			EP-----1274701 A1	HCAPLUS
Astrazeneca Ab	2001			CN-----1433411 A	HCAPLUS
Astrazeneca Ab	2001			BR---200109922 A	
Astrazeneca Ab	2001			AU---200146997 A	

Astrazeneca Ab	2001			US-0 @0 97 A $ 0	#3 |x f!E *0
Astrazeneca Ab	2001			MX--2002009885 A1	
Astrazeneca Ab	2001			NO---200204774 A	
Astrazeneca Ab	2001			ZA---200207700 A	
Astrazeneca Ab	2001			KR--2003005264 A	
Astrazeneca Ab	2001			JP--2003530393 A	
Astrazeneca Ab	2001			US-0 @0 93 A $ 0	#3 |x f!E *0
Astrazeneca Ab	2001			US-0 @0 93 A $ 0	#3 |x f!, *0
Astrazeneca Ab	2001			US-----6525070 B2	HCAPLUS
Neurogen Corp	2001			WO-----0160806 A2	HCAPLUS
Neurogen Corp	2001			EP-----1255740 A2	HCAPLUS
Neurogen Corp	2001			CN-----1400970 A	
Neurogen Corp	2001			BR----20008363 A	
Neurogen Corp	2001			AU---200138494 A	
Neurogen Corp	2001			MX--2002007868 A1	
Neurogen Corp	2001			SK---200201154 A3	
Neurogen Corp	2001			CZ---200202739 A3	
Neurogen Corp	2001			NO---200203869 A	
Neurogen Corp	2001			ZA---200206103 A	
Neurogen Corp	2001			US-0 @0 03 A $ 0	#3 |x f!E *0
Neurogen Corp	2001			HU---200301573 A2	HCAPLUS
Neurogen Corp	2001			KR--2003031886 A	
Neurogen Corp	2001			JP--2004500383 A	
Novo Nordisk AS	2003			WO----03024929 A1	HCAPLUS
Novo Nordisk AS	2003			EP-----1430027 A2	HCAPLUS
Novo Nordisk AS	2003			EP-----1434765 A1	HCAPLUS
Novo Nordisk AS	2003			AU--2002328797 A1	
Novo Nordisk AS	2003			US-0 @0 97 A1$ 0	#3 |x f!E *0
Ortho-McNeil Pharmaceut	2002			WO-----0010997 A1	HCAPLUS
Ortho-McNeil Pharmaceut	2002			EP----11079665 A1	
Ortho-McNeil Pharmaceut	2002			US-0 @0 65 A1$ 0	#3 |x f!t *0
Ortho-McNeil Pharmaceut	2002			JP--2002523413 A	
Ortho-McNeil Pharmaceut	2002			US-----6562847 B1	HCAPLUS
Ortho-McNeil Pharmaceut	2002			AU-----9955747 A	HCAPLUS

```
=> d his

     (FILE 'HCAPLUS' ENTERED AT 12:36:19 ON 22 JUN 2007)
               DEL HIS Y

     FILE 'HCAPLUS' ENTERED AT 14:13:31 ON 22 JUN 2007
L1             1 US20060178375/PN OR (US2005-561115 OR JP2003-184879 OR WO2004-J

     FILE 'HCAPLUS' ENTERED AT 14:15:00 ON 22 JUN 2007

     FILE 'STNGUIDE' ENTERED AT 14:16:00 ON 22 JUN 2007

     FILE 'REGISTRY' ENTERED AT 14:16:29 ON 22 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 14:16:30 ON 22 JUN 2007
L2             TRA L1 1- RN :      145 TERMS

     FILE 'REGISTRY' ENTERED AT 14:16:30 ON 22 JUN 2007
L3           145 SEA L2
L4           103 L3 AND NR>=2
L5           970 C15H20N4O
L6            11 L5 AND NC5/ES AND NCNC3/ES
L7             0 L6 AND L3
L8             0 L5 AND L3

     FILE 'STNGUIDE' ENTERED AT 14:18:25 ON 22 JUN 2007

     FILE 'REGISTRY' ENTERED AT 14:23:32 ON 22 JUN 2007
L9               STR
L10           50 L9
```

```
L11       51529 L9 FULL
L12             STR L9
L13            50 L12
L14            50 L12 SAM SUB=L11
L15         47061 L12 FULL SUB=L11
L16          4468 L11 NOT L15
L17             STR L9
L18            40 L17 SAM SUB=L16
L19             STR L17
L20            28 L19 SAM SUB=L16

     FILE 'STNGUIDE' ENTERED AT 14:46:29 ON 22 JUN 2007

     FILE 'REGISTRY' ENTERED AT 14:47:48 ON 22 JUN 2007
L21           491 L19 FULL SUB=L16
                  SAV TEM L21 J115S1/A
                  SAV TEM L16 J115BC1/A
L22               STR L19
L23             5 L22 SAM SUB=L16
L24           120 L22 FULL SUB=L16
                  SAV TEM J115S2/A L24
L25           610 L21,L24

     FILE 'STNGUIDE' ENTERED AT 14:52:23 ON 22 JUN 2007

     FILE 'REGISTRY' ENTERED AT 14:53:49 ON 22 JUN 2007
L26             5 L25 AND L3

     FILE 'STNGUIDE' ENTERED AT 14:55:04 ON 22 JUN 2007

     FILE 'REGISTRY' ENTERED AT 14:56:03 ON 22 JUN 2007
L27               STR L22
L28             5 L27 SAM SUB=L11
L29           127 L27 FULL SUB=L11
                  SAV TEM J115S3/A L29
L30           622 L25,L29
L31             5 L30 AND L3

     FILE 'HCAPLUS' ENTERED AT 14:57:57 ON 22 JUN 2007
L32            63 L30
                  E OHTAKE N/AU
L33            74 E3,E16
                  E NORIZAKU O/AU
                  E E NAYA A/AU
                  E NAYA A/AU
L34            25 E3,E5
                  E NAYA N/AU
                  E AKIRA N/AU
L35             3 E9
                  E HAGA Y/AU
L36           394 E3-6
                  E HAGA YUGI/AU
                  E HAGA YUJI/AU
L37            20 E3
                  E HAGA N/AU
L38             7 E5
                  E YUJI H/AU
                  E YUJI N/AU
L39            17 E6
                  E JITSUOKA M/AU
L40            12 E4
                  E JITSUOKA N/AU
                  E E MAKOTO J/AU
                  E SUGA T/AU
L41           170 E3-4
                  E SUGA TAKUYA/AU
```

```
L42             5 E3
                  E SUGA N/AU
L43             5 E3,E7
                  E TAKUYA S/AU
                  E TAKUYA N/AU
                  E YOSHIMOTO R/AU
L44            21 E3,E6-7
                  E YOSHIMOTO N/AU
L45            71 E3-4
                  E RYO Y/AU
                  E RYO N/AU
                  E TOKITA S/AU
L46            60 E3,E14
                  E TOKITA N/AU
L47             3 E5
                  E SHIGERU T/AU
                  E KANATANI A/AU
L48           105 E3-5
                  E KANATANI N/AU
L49             1 E3
                  E AKIO K/AU
                  E AKIKO K/AU
                  E AKIKO N/AU
                  E AKIO N/AU
L50          1824 (BANYU OR BAN YU)/CS,PA

     FILE 'STNGUIDE' ENTERED AT 15:05:17 ON 22 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 15:06:44 ON 22 JUN 2007
L51             3 L32 AND L1,L33-50
L52            60 L32 NOT L51

     FILE 'STNGUIDE' ENTERED AT 15:07:50 ON 22 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 15:08:49 ON 22 JUN 2007

     FILE 'STNGUIDE' ENTERED AT 15:10:15 ON 22 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 15:12:27 ON 22 JUN 2007

     FILE 'STNGUIDE' ENTERED AT 15:12:52 ON 22 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 15:16:13 ON 22 JUN 2007
L53            44 L52 AND (PD<=20040624 OR AD<=20040624 OR PRD<=20040624)

     FILE 'STNGUIDE' ENTERED AT 15:17:55 ON 22 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 15:21:50 ON 22 JUN 2007
               SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 15:22:33 ON 22 JUN 2007
L54           448 E1-448

     FILE 'STNGUIDE' ENTERED AT 15:26:44 ON 22 JUN 2007

     FILE 'REGISTRY' ENTERED AT 16:09:26 ON 22 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 16:09:49 ON 22 JUN 2007

=> => b reg
FILE 'REGISTRY' ENTERED AT 16:19:40 ON 27 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
```

provided by InfoChem.

STRUCTURE FILE UPDATES: 26 JUN 2007 HIGHEST RN 939408-72-7
DICTIONARY FILE UPDATES: 26 JUN 2007 HIGHEST RN 939408-72-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l5
L1 STR



VAR G1=C/N
REP G2=(0-3) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L2 (51529)SEA FILE=REGISTRY SSS FUL L1
L3 STR



REP G2=(0-3) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

```
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  13

STEREO ATTRIBUTES: NONE
L4  (     47061)SEA FILE=REGISTRY SUB=L2 SSS FUL L3
L5         4468 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 NOT L4


=> b hcap
FILE 'HCAPLUS' ENTERED AT 16:19:47 ON 27 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 27 Jun 2007  VOL 147 ISS 1
FILE LAST UPDATED: 26 Jun 2007  (20070626/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs fhitstr l17 tot

L17  ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:513745  HCAPLUS
DN   145:1056
TI   Treatment of stroke with histamine H3 inverse agonists or histamine H3
     antagonists
IN   Seabrook, Guy R.; Koblan, Ken S.; Ho, Tony Wei-Hsiu
PA   Merck & Co., Inc., USA
SO   PCT Int. Appl., 17 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     --------------      ----   --------   --------------------   --------
PI   WO2006058023         A2    20060601   2005WO-US42365         20051118
     WO2006058023         A3    20060914
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRAI 2004US-630513P       P     20041123
AB   Histamine H3 inverse agonists or histamine H3 antagonists are useful,
     alone or in combination with an anti-stroke agent, for treating stroke.
```

Preparation of histamine H3 inverse agonist 2-(1-cyclopentylpiperidine-4-yloxy)-5-(4-cyanophenyl)pyrimidine is included.

IT **832734-48-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(histamine H3 inverse agonists and histamine H3 antagonists for treatment of stroke, and use with other agents)

RN 832734-48-2 HCAPLUS
CN Benzonitrile, 4-[2-[(1-cyclopentyl-4-piperidinyl)oxy]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1288664 HCAPLUS
DN 144:36366
TI Preparation of quinazoline derivatives as histamine H3 receptor antagonists
IN Mizutani, Takashi; Nagase, Tsuyoshi; Sato, Nagaaki; Kanatani, Akio; Tokita, Shigeru
PA Banyu Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 233 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005115993	A1	20051208	2005WO-JP10291	20050530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU2005247808	A1	20051208	2005AU-0247808	20050530
CA---2569081	A1	20051208	2005CA-2569081	20050530
EP---1757594	A1	20070228	2005EP-0745824	20050530
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
CN---1960977	A	20070509	CN 2005-80017630	20050530
PRAI 2004JP-0162459	A	20040531		
2005WO-JP10291	W	20050530		

OS MARPAT 144:36366
GI



I





II

AB Title compds. I [R1 = aryl, aralkyl, alkoxy, etc.; further details on R1 are given.; R2, R3 = H, amino, alkylamino, etc.; R4 = Q1, etc.; R5 = H, alkyl, hydroxy, etc.; R7, R8 = alkyl, arylalkyl, heteroarylalkyl, with the proviso that R7 and R8 are not alkyl simultaneously; X1 = NH, O, S; Y = N, C; Ar = optionally substituted aryl, heteroaryl with alkyl, alkoxy, halo; ring A = Ph, heteroaryl containing N, O] were prepared For example, reaction of 2-(4-hydroxyphenyl)-3,8-dimethyl-4(3H)-quinazolinone, e.g., prepared from 3-methyl-2-aminobenzoic acid in 3 steps, with 1-chloro-3-bromopropane and K2CO3 followed by in-situ treatment with piperidine afforded compound II [R = methyl; X = piperidin-1-yl]. In histamine analog binding inhibition assays, the IC50 value of compound II [R = H; X = pyrrolidin-1-yl] was 0.68 nM. Compds. I are claimed useful for the treatment of diabetes, obesity, etc.

IT **870997-73-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazoline derivs. as histamine H3 antagonists for treatment of obesity, diabetes, etc.)

RN 870997-73-2 HCAPLUS

CN Pyridine, 2-[(1-cyclobutyl-4-piperidinyl)oxy]-5-ethenyl- (9CI) (CA INDEX NAME)



RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1123759 HCAPLUS

DN 143:379851

TI Treatment of tremor or other movement disorder with histamine H3 inverse agonists or histamine H3 antagonists

IN Marino, Michael J.; Seabrook, Guy R.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
---	---	---	---	---

PI WO2005097111 A2 20051020 2005WO-US09562 20050322
WO2005097111 A3 20060427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP---1732544 A2 20061220 2005EP-0732633 20050322
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
PRAI 2004US-556803P P 20040326
2004US-561188P P 20040409
2004US-629099P P 20041118
2005WO-US09562 W 20050322

AB Histamine H3 inverse agonists or histamine H3 antagonists are useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders, including tremor, such as essential tremor, and tremor associated with Parkinson's disease, cranofacial trauma, multiple sclerosis, stroke, dystonia, and neuropathic, toxic or drug-induced tremor. Preparation and activity of 2-(1-cyclopentylpiperidin-4-yloxy)-5-(4-cyanophenyl)pyrimidine is included.

IT **832734-48-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(histamine h3 inverse agonists or antagonists for treatment of tremor or other movement disorder, and use with other agents)

RN 832734-48-2 HCAPLUS
CN Benzonitrile, 4-[2-[(1-cyclopentyl-4-piperidinyl)oxy]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:74112 HCAPLUS
DN 142:176868
TI Preparation of heterocyclic compounds as histamine H3 receptor antagonists/inverse agonists
IN Ohtake, Norikazu; Naya, Akira; Haga, Yuji; Jitsuoka, Makoto; Suga, Takuya; Yoshimoto, Ryo; Tokita, Shigeru; Kanatani, Akio
PA Banyu Pharmaceutical Co., Ltd, Japan
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005007644	A1	20050127	2004WO-JP09272	20040624

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

AU2004257025	A1	20050127	2004AU-0257025	20040624
CA---2529790	A1	20050127	2004CA-2529790	20040624
EP---1642898	A1	20060405	2004EP-0746741	20040624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN---1812981	A	20060802	CN 2004-80018205	20040624
US2006178375	A1	20060810	2005US-0561115	20051215
PRAI 2003JP-0184879	A	20030627		
2004WO-JP09272	W	20040624		

OS MARPAT 142:176868
GI



I

T1 =



AB The title compds. I [each of X1, X2 and X3 independently represents N or CH; W represents the formula T1, etc.; m = 0 - 3; and Y represents (O)jL1(CO)p(M)iQ1; j, p, i = 0 or 1; L1 = alkylene, single bond; M = O, etc.; Q1 = cyano, etc; R = cyano, etc.] are prepared Thus, 2-(1-cyclopentylpiperidin-4-yloxy)-5-(4-cyanophenyl)pyrimidine was prepared in a multistep process from 2-chloro-5-bromopyrimidine and 1-tert-butoxycarbonyl-4-hydroxypiperidine. In an in vitro assay for inhibition of a histamine analog binding to the H3 receptors, compds. of this invention showed IC50 values of 0.45 nM to 1.9 nM. Processes for preparing I are disclosed. Formulations are given.

IT **832734-48-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as histamine H3 receptor antagonists/inverse agonists)

RN 832734-48-2 HCAPLUS
CN Benzonitrile, 4-[2-[(1-cyclopentyl-4-piperidinyl)oxy]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:31:02 ON 27 JUN 2007)

```
     FILE 'REGISTRY' ENTERED AT 15:32:15 ON 27 JUN 2007
                ACT J115BC1/A
               ---------
L1                STR
L2   (      51529)SEA FILE=REGISTRY SSS FUL L1
L3                STR
L4   (      47061)SEA FILE=REGISTRY SUB=L2 SSS FUL L3
L5           4468 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 NOT L4
               ---------

     FILE 'HCAPLUS' ENTERED AT 15:34:02 ON 27 JUN 2007
L6            406 L5
                  E HISTAMINE/CT
                  E E16+ALL
L7           1190 E9+OLD
                  E HISTAMINE H3 ANTAGONISTS/CT
                  E E3+ALL
                  E E2+ALL
L8            482 E4+OLD
L9             14 L6 AND L7-8
                  SEL AN 1-12 14
L10            13 E1-26 AND L9

     FILE 'STNGUIDE' ENTERED AT 15:37:05 ON 27 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 15:37:59 ON 27 JUN 2007
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 15:38:08 ON 27 JUN 2007
L11           194 E27-220
                  DEL SEL Y
L12           178 L11 AND NC5/ES

     FILE 'HCAPLUS' ENTERED AT 15:41:32 ON 27 JUN 2007
L13             7 L10 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)
                  SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 15:42:09 ON 27 JUN 2007
L14            27 E1-27

     FILE 'STNGUIDE' ENTERED AT 15:42:42 ON 27 JUN 2007

     FILE 'REGISTRY' ENTERED AT 15:44:08 ON 27 JUN 2007
L15             8 L14 AND (C22H26N6O3 OR C21H24N4O OR C23H24F3N5O2 OR C24H28N4O2
L16             2 L15 AND (C16H22N2O OR C21H24N4O)

     FILE 'HCAPLUS' ENTERED AT 15:49:54 ON 27 JUN 2007
L17             4 L16

     FILE 'STNGUIDE' ENTERED AT 15:50:56 ON 27 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 15:55:55 ON 27 JUN 2007

     FILE 'STNGUIDE' ENTERED AT 15:57:01 ON 27 JUN 2007

     FILE 'REGISTRY' ENTERED AT 16:19:40 ON 27 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 16:19:47 ON 27 JUN 2007

=> => d his

     (FILE 'HOME' ENTERED AT 13:23:06 ON 28 JUN 2007)

     FILE 'REGISTRY' ENTERED AT 13:45:47 ON 28 JUN 2007
                ACT J115BC1/A
```

```
                ---------
L1                STR
L2   (     51529)SEA FILE=REGISTRY SSS FUL L1
L3                STR
L4   (     47061)SEA FILE=REGISTRY SUB=L2 SSS FUL L3
L5          4468 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 NOT L4
                ---------
                ACT J115S1/A
                ---------
L6                STR
L7   (     51529)SEA FILE=REGISTRY SSS FUL L6
L8                STR
L9   (     47061)SEA FILE=REGISTRY SUB=L7 SSS FUL L8
L10  (      4468)SEA FILE=REGISTRY ABB=ON  PLU=ON  L7 NOT L9
L11               STR
L12          491 SEA FILE=REGISTRY SUB=L10 SSS FUL L11
                ---------

     FILE 'HCAPLUS' ENTERED AT 13:46:54 ON 28 JUN 2007
L13            52 L12
L14            40 L13 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)
L15             1 US2006178375/PN
L16             1 L14 AND L15
L17            39 L14 NOT L16
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 13:48:51 ON 28 JUN 2007

     FILE 'STNGUIDE' ENTERED AT 13:53:23 ON 28 JUN 2007

     FILE 'REGISTRY' ENTERED AT 13:55:15 ON 28 JUN 2007
                ACT J115S2/A
                ---------
L18               STR
L19  (     51529)SEA FILE=REGISTRY SSS FUL L18
L20               STR
L21  (     47061)SEA FILE=REGISTRY SUB=L19 SSS FUL L20
L22  (      4468)SEA FILE=REGISTRY ABB=ON  PLU=ON  L19 NOT L21
L23               STR
L24          120 SEA FILE=REGISTRY SUB=L22 SSS FUL L23
                ---------
                ACT J115S3/A
                ---------
L25               STR
L26  (     51529)SEA FILE=REGISTRY SSS FUL L25
L27               STR
L28          127 SEA FILE=REGISTRY SUB=L26 SSS FUL L27
                ---------
L29          618 L28,L12
L30               STR L11
L31               STR L27
L32           11 (L30 OR L31) SAM SUB=L29
L33          141 (L30 OR L31) FULL SUB=L29
                SAV TEM L33 J115S4/A
L34          477 L29 NOT L33

     FILE 'HCAPLUS' ENTERED AT 13:59:11 ON 28 JUN 2007
L35            32 L34 AND L17
                DEL SEL Y
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 13:59:46 ON 28 JUN 2007
L36          318 E1-318

     FILE 'STNGUIDE' ENTERED AT 14:02:21 ON 28 JUN 2007
```

FILE 'REGISTRY' ENTERED AT 14:13:05 ON 28 JUN 2007

=> b reg
FILE 'REGISTRY' ENTERED AT 14:14:06 ON 28 JUN 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0
DICTIONARY FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l34
L6 STR



VAR G1=C/N
REP G2=(0-3) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L7 (51529)SEA FILE=REGISTRY SSS FUL L6
L8 STR



REP G2=(0-3) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L9 (47061)SEA FILE=REGISTRY SUB=L7 SSS FUL L8
L10 (4468)SEA FILE=REGISTRY ABB=ON PLU=ON L7 NOT L9
L11 STR



REP G2=(0-3) C
NODE ATTRIBUTES:
NSPEC IS RC AT 14
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 3
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 8
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L12 491 SEA FILE=REGISTRY SUB=L10 SSS FUL L11
L25 STR



VAR G1=C/N
REP G2=(0-3) C

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L26 (51529) SEA FILE=REGISTRY SSS FUL L25
L27 STR



REP G1=(0-1) O
REP G2=(0-3) C
REP G3=(0-1) AK
REP G4=(0-1) N
NODE ATTRIBUTES:
NSPEC IS RC AT 18
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 3
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 8
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L28 127 SEA FILE=REGISTRY SUB=L26 SSS FUL L27
L29 618 SEA FILE=REGISTRY ABB=ON PLU=ON (L28 OR L12)
L30 STR



REP G2=(0-3) C
NODE ATTRIBUTES:
NSPEC IS RC AT 14
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 3
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 8
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

L31 STR



REP G1=(0-1) O
REP G2=(0-3) C
REP G3=(0-1) AK
REP G4=(0-1) N
NODE ATTRIBUTES:
NSPEC IS RC AT 18
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 3
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 8
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L33 141 SEA FILE=REGISTRY SUB=L29 SSS FUL (L30 OR L31)
L34 477 SEA FILE=REGISTRY ABB=ON PLU=ON L29 NOT L33

=>